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Abstract
Cannabis sativa has been used as an anti-inﬂammatory plant for millennia. However until the elucidation
of the chemistry of its constituents and the discovery of the endogenous cannabinoid system only a limited
amount of research had been done on the eﬀects of the plant or its constituents on inﬂammation. In the
present overview we summarize our work on the eﬀects of the non-psychotropic cannabidiol (CBD) and of
a synthetic cannabidiol-derived acid (HU-320) in animal models of arthritis. Both compounds block
progression of the disease, when administered after its onset. Cannabidiol was equally eﬀective was
administered i.p. or orally. Signiﬁcant protection of the joints against severe damage was noted. In vitro
cannabidiol reduced lymphocyte proliferation, and TNF-a formation and blocked zymosan-triggered
production of reactive oxygen intermediates (ROI). Ex vivo lymph node cells from CBD-treated mice
showed a decrease of collagen II-speciﬁc proliferation and IFN-c production. A decreased release of TNF
by knee synovial cells was also noted. A synthetic cannabidiol derivative, HU-320 also inhibited production
of TNF and ROI by mouse macrophages in vitro and suppressed in vivo rise in serum TNF following
endotoxin challenge. HU-320 showed no activity in a standard assay for THC-type psychotropic eﬀects.
These results suggest that CBD and HU-320 hold promise as potential novel anti-inﬂammatory agents.
Abbreviations: 2-AG – 2-arachidonoylglycerol; CBD – cannabidiol; CIA – collagen-induced arthritis; CII –
collagen type II; IFN – interferon; IL – interleukin; LPS – lipopolysaccharide; NO – nitric oxide; ROI –
reactive oxygen intermediates; THC – tetrahydrocannabinol; TNF – tumor necrosis factor
Introduction
Cannabis sativahas been used as an anti-inﬂammatory
plant for millennia. Evidence from populations with
various cultural backgrounds is now available. Thus,
Campbell Thompson (1949) has compiled an Assyr-
ian herbal based on fragments of cuneiform plant lists
and tablets, most of the era of Ashurbanipal (died
626 B.C.). Cannabis is mentioned as a drug used in
numerous diseases. Its fumes were a drug for the
‘poison of all limbs’ – presumably arthritis. Centu-
ries later Pliny the Elder mentions that the root
boiled in water eases cramped joints as well as gout
(Brunner, 1973). Pedanius Dioscorides (died about
199 A.D.) in his famous Herbal, which was one of the
basic books on drugs throughout the Middle Ages,
mentions that cannabis roots dissolve edema and
assuage inﬂammations (Dioscorides, 1934). In India
cannabis was used both orally and as poultices applied
over inﬂamed, painful parts of the body (Chopra and
Chopra, 1957). The British physician O’Shaugnessy
meticulously recorded the popular andmedical uses of
various cannabis preparations in India and later con-
ducted animal and human experiments with them. He
described the treatment of patients with a variety of
diseases, chosen to conﬁrm well established local
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traditions (O’Shaugnessy, 1843;Mechoulam, 1986). In
the case of rheumatism two out of three cases were
‘much relieved of their rheumatism; they were dis-
charged quite cured in 3 days after.’ The third patient’
experienced no eﬀect whatsoever, and on further
inquiry it was found that ‘he was habituated to the use
of gunjah in the pipe.’ This was an early report on
tolerance, which was also found in a few other cases.
The reports by O’Shaugnessy were received in
England with considerable interest and gradually
Indian hemp became an accepted drug in therapy.
Donovan (1845) reported that cannabis tincture
made from Indian, but not from local cannabis
(hemp), was highly eﬀective in cases of neuralgic
pain in the arms and ﬁngers, inﬂammation of the
knee and sciatica. In a mid-19th century review
Christison (1851) concluded that cannabis tincture
was particularly helpful in rheumatic pain. About
40 years later Queen Victoria’s physician Russell
Reynolds (1890) summarized his long clinical
experience: ‘... Indian hemp when pure and
administered carefully is one of the most valuable
medicines we posses... ...In almost all painful
maladies ... [it] was by far the most useful of
drugs’. Looking back, these reports certainly
indicate eﬃcacy, but the varying levels of the then
unknown active principle most probably prevented
wide use of the drug.
Although occasional articles on the therapeutic
potential of cannabis continued to be published
for decades after the turn of the 20th century, its
medical use slowly declined. There are two major
reasons for this decline:
A. The active constituents of cannabis had not
been isolated in pure form. Hence, crude plant
preparations or extracts had to be used. Cannabis
is notorious for its chemical variability and its easy
deterioration. Therefore, reproducible clinical
eﬀects were not always obtained.
B. Legally, in many countries, cannabis was linked
to the opiates. The use of these drugs was oﬃcially
controlled and frequently made diﬃcult. However,
the opiates due to their medical indispensability
continued to be widely employed; cannabis use
declined.
Cannabis sativa and Papaver somniferum have
been for a long time the source of the most widely
used illegal drugs. However research on Cannabis
sativa has always lagged behind that on Papaver
somniferum.Thus,whilemorphinewasisolatedfrom
opium early in the 19th century, tetrahydro-
cannabinol (THC)wasnot fully identiﬁeduntil 1964
(Gaoni and Mechoulam, 1964); the ﬁrst opiate
receptorsweredescribedinthe1970s,butthoseofthe
cannabinoids were not discovered for another
20 years (Devane et al., 1988; Matsuda et al., 1990;
Munro et al., 1993). The ﬁrst endogenous opiates
were isolated in the 1970s; the endocannabinoids –
in the 1990s (Devane et al., 1992; Mechoulam et
al., 1995; Sugiura et al., 1995). Why the discrep-
ancy? The reasons are mostly technical. Morphine
forms numerous easily isolable, crystalline salts,
while the active compounds in cannabis were
known to be present in a complex oily mixture
from which it was diﬃcult to obtain pure constit-
uents with the methods then available. In the 1930s
and early 1940s Todd in the UK and Adams in the
US reisolated cannabinol, which is probably an
artifact and not an original natural product, and
elucidated its structure (Todd, 1946; Adams 1941–
1942). Cannabidiol (CBD), a constituent which
showed no psychotropic activity in several animal
assays, was also isolated, although its structure
remained in doubt. However the constituent that
causes the typical cannabis eﬀects was not ob-
tained in a pure form and could not be fully
identiﬁed.
In the early 1960s we took a new look at the
problem. By then better chromatographic tech-
niques had evolved and we were able to separate
numerous new cannabinoids – a term which we
suggested then and which has received wide accep-
tance. First, we reisolated cannabidiol and obtained
the psychotropic constituent – D9-THC – in pure
form. Their structures were determined (Mechoulam
and Shvo, 1963; Gaoni and Mechoulam, 1964).
Some of the cannabinoids which were isolated by
our and other groups during that period are pre-
sented in Figure 1. The structures and relative ste-
reochemistry were elucidated by the then novel
techniques of NMR and mass spectrometry. The
absolute stereochemistry of D9-THC and of CBD
and hence of all other cannabinoids with which they
have been chemically related, was established by
chemical correlation (Mechoulam andGaoni, 1967).
About 70 cannabinoid-type constituents are
known (Mechoulam, 1970; Turner et al., 1980). All
of them are essentially variations on the structures
represented in Figure 1. The chemistry, biochem-
istry, pharmacology and clinical eﬀects of THC
have been investigated in great detail (Mechoulam
and Ben-Shabat, 1999). A considerable amount of
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work has also been reported on CBD (Mechoulam
and Hanus, 2002; Mechoulam et al., 2002). How-
ever we still know very little about the rest of the
constituents. Initially, for obvious reasons, most of
the pharmacological work on the cannabinoids
centered on the central nervous system (CNS),
with emphasis on the psychotropic eﬀects. Grad-
ually reports covering other areas appeared. The
present overview presents data on the eﬀects of
some cannabinoids in inﬂammation, with empha-
sis on those from our laboratories. For recent
publications and general reviews on cannabinoids
and the immune system and inﬂammation (Klein
et al., 2003; Lambert et al., 2002; Melck et al., 2002;
Roth et al., 2002; Cabral et al., 2001). Of particular
interest and possible therapeutic importance of
cannabinoids are the advances made in multiple
sclerosis (Roth et al., 2002). This area is however
beyond the scope of this overview.
For nearly 2 decades after the identiﬁcation
of D9-THC as the psychoactive constituent of
cannabis, its mechanism of action remained an
enigma. Initially it was assumed that cannabis action
is somehow associated with membrane perturba-
tion. However in 1984 Howlett, using a neuro-
blastoma cell line as a model system, demonstrated
that cannabinoids interact with the adenylate cy-
clase second messenger pathway in an inhibitory
fashion (Howlett and Fleming, 1984). The level of
potency of a variety of cannabinoids to inhibit
adenylate cyclase paralleled cannabinoid eﬀects in
animal models and in humans. Stereospeciﬁcity
was also demonstrated using the HU-210 and
HU-211enantiomers (Howlett etal., 1990;Mechoulam
et al., 1988). This line of research culminated in the
discovery in the brain of speciﬁc, high aﬃnity
cannabinoid binding sites, whose distribution is
consistent with the pharmacological properties of
psychotropic cannabinoids (Devane et al., 1988).
Shortly thereafterMatsuda et al. (1990) cloned this
cannabinoid receptor which is now designated
CB1. A peripheral receptor (CB2) was identiﬁed in
the spleen (Munro et al., 1993).
The existence of cannabinoid receptors sug-
gested the presence of endogenous ligands. In order
to look for such ligands, a speciﬁc, highly potent
radiolabelled cannabinoid probe [3H]HU-243 was
prepared (Devane et al., 1992b). Porcine brain
fractions were found to compete with this probe for
binding to cannabinoid receptors. Chromatogra-
phy of such brain fractions led to the identiﬁcation
of a family of unsaturated fatty acid ethanolamides
(Figure 2). The ﬁrst active ligand isolated was
arachidonoylethanolamide (anandamide) (Devane
et al., 1992a). A second endocannabinoid – 2-
arachidonoyl glycerol (2-AG) was shortly thereaf-
ter identiﬁed in the periphery and in the brain
(Mechoulam et al., 1995; Sugiura et al., 1995).
Structurally there is little in commonbetweenTHC
and the endocannabinoids. The plant cannabinoids
are terpenophenols, while the endocannabinoids are
fatty acid derivatives. Yet, pharmacologically they
have much in common. Both THC and anandamide
cause a typical tetrad of physiological eﬀects: hypo-
thermia, hypomotility, antinociception and catalepsy
(Fride and Mechoulam, 1993). In most behavioral
tests, anandamide and 2-AG are somewhat less potent
than THC.
Recently evidence has been presented showing
that additional cannabinoid receptors are present
both in theCNSand in the periphery, but these claims
have not been yet substantiated (Howlett et al., 2002).
Some anti-inﬂammatory eﬀects of cannabidiol
Our present knowledge does not throw light on all
cannabinoid actions. Thus cannabidiol, a major
Figure 1. Some plant cannabinoids.
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plant constituent, which does not bind to either
CB1 or CB2, has a plethora of pharmacological
actions, but causes no THC-like psychotropic
eﬀects. However it is an anti-convulsive and anti-
anxiety agent, both in animals and in humans. It
has been reported to cause sleepiness and has
recently been shown to prevent nausea in animal
models. Its chemistry and pharmacological eﬀects
have recently been reviewed (Mechoulam and
Hanus, 2002; Mechoulam et al., 2002). Its mech-
anism(s) of action are unknown, but it is quite
possible that it binds to one or more of the puta-
tive cannabinoid receptors recently put forward
(Howlett et al., 2002).
A few reports on the in vitro eﬀects of CBD in
immune systems have appeared. Watzl et al. (1991)
reported that CBD reduced the levels of both tumor
necrosis factor (TNF-a) and IL-1 in human
peripheral blood mononuclear cells. However con-
centrations of CBD, comparable to plasma levels
found after smoking marijuana (10–100 ng/ml),
increased the concentrations of IFN-c; at higher
concentrations (5–20 microgr/ml) a complete inhi-
bitionof the synthesis and/or release of this cytokine
was observed. This biphasic eﬀect is quite typical for
cannabinoids (Sulcova et al., 1998). Srivastava et al.
(1998) found that CBD strongly inhibited IL-10
production by a human leukemic T cell line. An
earlier report indicated that CBD antagonized tet-
radecanoylphorbol (TP A)-induced erythema of
mouse skin (Formukong et al., 1988). These reports,
the very low toxicity (Rosenkrantz et al., 1981) and
absence of psychotropic eﬀects of CBD, led us to
further investigate its immunosuppressive and anti-
inﬂammatory actions.
First we looked into some in vitro eﬀects of
CBD. As macrophages are the main producer of
TNF during inﬂammation we examined the eﬀect
of CBD on TNF production by mouse macro-
phages after lipopolysaccharide (LPS) activation.
At a dose of 6 mg/ml CBD a 72% suppression
ofTNF production was recorded (unpublished re-
sults). Similarly generation of nitric oxid (NO) by
LPS-activated macrophages was markedly sup-
pressed (88% with 4 mg/ml) (unpublished results).
Treatment of mouse granulocytes (stimulated with
Zymosan) with 6 mg/ml CBD suppressed the
production of reactive oxygen intermediates (ROI)
by 45%, if the cannabinoid was applied simulta-
neously with Zymosan, or by 92% if it was added
1 hr before the activation (Malfait et al., 2000).
CBD also markedly suppressed Con-A induced
in vitro proliferation of murine splenic lympho-
cytes. At a dose of 5 lg/ml a 90% suppression was
noted (Malfait et al., 2000). In in vivo experiments
high levels ofTNF were found in serum, 90 min-
utes after LPS injection. When CBD was injected,
either i.p. or s.c., together with LPS a marked
suppression was noted (81 and 89% respectively).
Then we examined the eﬀects of CBD in an
animal model of arthritis murine collagen-induced
arthritis (CIA) (Malfait et al., 2000). In this model
DBA/1 mice are immunized with type II collagen
in complete Freund’s adjuvant. This type of col-
lagen causes diﬀerent types of arthritis depending
on its source. Collagen from a bovine source causes
classical acute arthritis, while murine collagen leads
to chronic relapsing (homologous) CIA. The latter
model has a clinical pattern, which resembles more
closely the human disease than the classical acute
(heterologous) CIA. Thus, the clinical score in the
homologous model in mice typically alternates for
several weeks. Overall, human arthritis is also
chronic relapsing and progressive. Both humoral
and cellular mechanisms are involved in the im-
mune response to collagen-induced arthritis; the
Figure 2. Endogenous cannabinoids.
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cellular response is T helper-1 mediated. The clini-
cal picture seen with this type of murine arthritis is
a rapid onset of joint inﬂammation, leading to
destruction of joint tissues and cartilage, and bone
erosions. TNF is involved in the pathogenesis of
CIA, as suppression of the inﬂammatory process by
blocking TNF is an eﬀective treatment. Indeed
clinical trials in patients based on TNF suppression
by various agents, such as anti-TNF monoclonal
antibodies, have led to positive results.
In the classical (heterologous) CIA, treatment
with CBD in mice started at the ﬁrst clinical signs of
the disease and was administered either i.p. daily
for 10 days at doses of 2.5, 5, 10 and 20 mg/kg or
orally at higher doses, namely 10, 25 and 50 mg/kg
in olive oil. In the chronic (homologous) CIA
treatment with CBD also started at the ﬁrst clinical
signs, but continued for 5 weeks either i.p. (doses of
5 or 10 mg/kg) or orally (doses of 25 mg/kg).
In both CIA models CBD had a dose-depen-
dent therapeutic eﬀect. In the classical model at
2.5 mg/kg no eﬀect was noted, while the 5.0 mg/kg
dose caused an optimal suppression of the disease.
The higher doses (10 and 20 mg/kg) had only a
slight therapeutic eﬀect. In the chronic model again
we also noted better results with the 5 mg/kg dose
than with the higher dose. This biphasic eﬀect, as
mentioned above, is quite typical for cannabinoids
in various assays and is probably due to stimula-
tion of Gs proteins at low doses and both Gs and
Gi stimulaion at high doses, with inhibition pre-
sumably overwhelming the stimulation.
I.p. and oral administration of CBD had a
comparable therapeutic eﬀect on established
arthritis in both models. However oral adminis-
tration required higher doses (25 mg/kg) than
those needed with i.p. doses (5 mg/kg).
Joints in the hind paws of mice with chronic
homologous CIA treated with CBD were assessed
and compared to those of control mice. In the
chronic assay the best results in the i.p. group were
noted with 5 mg/kg. While 30% of the animals in
the treated group retained normal hind feet, none of
the control was without damage. About 90% of the
hind feet in the control group showed arthritic
changes, but only 60% of the group injected with
CBD exhibited such changes, most of them being
less damaged than those in the control group. In the
group administered CBD orally, again, no animals
in the control group survived without any damage,
while 36% of the treated animals had no changes.
In several in vivo and in vitro assays we found that
CBD exerts a potent immunosuppressive eﬀect.
Thus, synovial cells from arthritic mice spontane-
ously produce large amounts ofTNF when cultured
in vitro. We compared the TNF production by the
CBD treated mice (i.p., 5 mg/kg, classical assay)
with the controls on day 10. The CBD treated-mice
produced signiﬁcantly less TNF than the control
mice (Malfait et al., 2000). These data are of con-
siderable importance as the synovium is the most
critical site of cytokine production in arthritis.
Draining lymph node cells from CBD-treated
arthritic DBA/1 mice when stimulated with colla-
gen II in vitro suppressed lymphocyte proliferation
and IFN-c production compared to controls.
The anti-inﬂammatory action of CBD is probably
due to a combination of factors, the major ones of
which are presumably the reduction of TNF in the
synovium and the lower levels of IFN-c in lymph
node cells. Immunosupression, especially of T-helper
1 response, is probably also of major importance.
As CBD has a very low toxicological proﬁle
and previously has been safely administered to
humans (in trials connected with neurological
diseases), its introduction in the clinic should be
relatively facile.
Cannabinoid acids
a. THC derived acids
A major metabolic route of THC, both in the
D9- and the D8-THC series, is oxidation at C-11,
initially leading to 11-0H-THC and then to THC-
11-oic acid (Agurell et al., 1986; Mechoulam et al.,
1973). Delta-8-THC-11-oic acid has anti-inﬂam-
matory properties (Burstein, 1989). As the 1,
1-dimethylheptyl homologs of THC are well known
to be more potent in numerous bioassays (mostly
in the CNS area) than the natural, pentyl constitu-
ents, we synthesized 1,1-dimethylheptyl-D8-THC-7-
oic acid (Burstein et al., 1992), which, under the
names CT-3 or ajulemic acid, has been extensively
evaluated for its anti-inﬂammatory properties
(Burstein, 2001). It reduces the accumulation of
leukocytes in a mouse model of acute inﬂamma-
tion, as well as the severity of adjuvant-induced
polyarthritis in rats. Ajulemic acid also attenuated
inﬂammation of joint tissue and damage to joint
cartilage and bone was prevented (Burstein, 2001).
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Although these results are promising, the clinical use
of ajulemic acid in chronic inﬂammation is doubtful.
Ajulemic acid binds to both cannabinoid receptors,
in particular to CB1 (Rhee et al., 1997). As it inhibits
adenylyl cyclase much less than THC, we assumed
that it may not have THC-like properties.
Unfortunately, it does show sedative eﬀects in
mice (Dajani et al., 1999) and in the speciﬁc can-
nabinoid assay in mice (the tetrad assay) it was as
active as THC (Sumariwalla et al., 2004). As anti-
inﬂammatory drugs for chronic conditions are not
necessarily administered in a hospital, but at
home, it is conceivable that a drug with THC-like
eﬀects may not be readily approved. Hence we
decided to synthesize and evaluate the comparable
acid in the CBD series.
b. CBD-DMH-7-oic acid
The synthesis of this acid is described in Figure 3
(unpublished data). It is based on the speciﬁc
epoxidation of the endocyclic double bond, leading
to a single epoxide, which after a number of steps
leads to the desired acid, code named HU-320.
First a psychotropic evaluation was undertaken
(Sumariwalla et al., 2004). Female mice were
injected i.p. with THC, ajulemic acid and HU-320
and tested in the standard cannabinoid (tetrad)
assay, measuring ambulation, immotility, hypo-
thermia and analgesia. Ajulemic acid and THC
showed signiﬁcant eﬀects on CNS mediated func-
tions. HU-320 was essentially inactive. Then we
evaluated HU-320 in a number of in vitro and
in vivo antiinﬂammatory models. Mice were immu-
nized by a single intradermal injection of bovine
collagen type II (CII). Arthritis appeared around
day 21 post immuniztion. HU-320 was adminis-
tered i.p. to the arthritic mice from day 1 of the
appearance of the disease for 10 days at doses of
0.5, 1 and 2 mg/kg. The paws of the mice were
assessed for clinical signs (redness and swelling)
following a standard scoring system. The clinical
score of the animals receiving the drug (1 and
2 mg/kg) was signiﬁcantly better than that of the
controls. Higher doses did not improve the results.
The paw thickness of the treated mice was also
signiﬁcantly lower than that of the controls. Oral
administration also improved the arthritis, how-
ever higher doses (40 mg/kg) were required. His-
tological examination indicated that the drug
oﬀered a signiﬁcant degree of protection against
joint damage. Reduction in synovial hyperplasia
Figure 3. Syntheses of CBD-7-oic acid and CBD-DMH-7-oic acid (HU-320).
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was also seen, and we noted a reduction in the
numbers of inﬁltrating immune cells, such as
monocytes, macrophages, neutrophiles and lym-
phocytes, as well as lowering of TNF levels
induced by endotoxin challenge. We assume that
the protection of the joint from cartilage loss and
bone damage is due to this lowering of the inﬂux
of immune cells and their inactivation at the site of
the disease (Sumariwalla et al., 2004).
In vitro observations paralleled the in vivo
results. Thus we noted that in several cell types
HU-320 down modulated the release of important
mediators of arthritis, such as TNF, IFN-c and
ROI, as seen previously with CBD. HU-320 also
suppressed in vitro the proliferative response of
lymph node cells primed with bovine CII, again
suggesting that the drug exerts (in part at least) its
anti-arthritic eﬀects by suppressing cellular im-
mune response to CII (Sumariwalla et al., 2004).
The resorcinol moiety confers anti-oxidant
properties to numerous cannabinoids (Hampson
et al., 1998). HU-320 likewise possesses such a
moiety and indeed causes anti-oxidative eﬀects, as
noted by the lowering of ROI levels in vitro.
Each of the various immune eﬀects seen with
HU-320 presumably contributes to the overall
powerful anti-rheumatic action. However the
molecular mechanism of its action, like that of
CBD, is still an enigma. Neither compound binds
to the 2 known cannabinoid receptors. It is quite
possible that both cannabidiol and HU-320 bind
to one of the several yet unidentiﬁed novel can-
nabinoid receptors, which have been assumed to
exist. Sancho et al. (2003) have shown that ananda-
mide inhibits nuclear factor-jB activation through a
cannabinoid receptor-independent pathway. Are the
compounds described now acting by the same route?
The toxicity of HU-320 has not yet been
determined. However since CBD has extremely
low toxicity in vivo, it is reasonable to assume that
its metabolites (including the acid) are also non-
toxic. As HU-320 is a homologue of this metab-
olite, its toxicity probably is also low.
Conclusion
Our recent work, described in part in this over-
view, indicates that the long known anti-inﬂam-
matory action of Cannabis sativa may be due in
part to the non-psychotropic constituent canna-
bidiol (and presumably also to its acidic metabo-
lite). Both cannabidiol and a synthetic cannabidiol
acid homolog (HU-320) are potent anti-inﬂam-
matory compounds in vitro and in vivo. Their
clinical development may possibly add new drugs
for rheumatoid arthritis.
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